Eversept Partners’s Kyntra Bio KYNB Stock Holding History

Eversept Partners’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,552	Closed	-$105K	–	73
2023 Q2	$105K	Buy	+1,552	New	+$642K	0.01%	70

Other funds holding KYNB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Eversept Partners's KYNB Position: Q3 2023 in Review

Eversept Partners sold out of Kyntra Bio (KYNB) in Q3 2023, closing a stake of 224 shares — an estimated $15.1K sold.

Eversept Partners first reported a position in KYNB in Q2 2023 and held it in 1 quarter. The position peaked at $15.1K in Q2 2023. 110 funds tracked by Wall St. Rank hold KYNB as of Q3 2023.

Eversept Partners reported no remaining Kyntra Bio position as of Q3 2023 after selling out during the quarter.
Eversept Partners sold 224 Kyntra Bio shares in Q3 2023, an estimated $15.1K.
Eversept Partners first reported a position in Kyntra Bio in Q2 2023 and held it in 1 quarter.
Eversept Partners's Kyntra Bio position peaked at $15.1K in Q2 2023.
110 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2023.

Based on Eversept Partners's 13F filing for Q3 2023, filed 14 Nov 2023.